How to buy Molecular Templates stock - 17 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Molecular Templates stock

Own Molecular Templates stock in just a few minutes.

Molecular Templates, Inc is a biotechnology business based in the US. Molecular Templates shares (MTEM) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Templates employs 236 staff and has a trailing 12-month revenue of around USD$18.8 million.

How to buy shares in Molecular Templates

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Molecular Templates. Find the stock by name or ticker symbol: MTEM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Molecular Templates reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Molecular Templates, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Molecular Templates. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Molecular Templates share price

Use our graph to track the performance of MTEM stocks over time.

Molecular Templates shares at a glance

Information last updated 2021-04-16.
52-week rangeUSD$7.51 - USD$18.44
50-day moving average USD$10.8241
200-day moving average USD$10.6144
Wall St. target priceUSD$16.29
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.789

Buy Molecular Templates shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Molecular Templates stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Molecular Templates financials

Revenue TTM USD$18.8 million
Gross profit TTM USD$-74,120,000
Return on assets TTM -40.13%
Return on equity TTM -129.23%
Profit margin 0%
Book value $1.187
Market capitalisation USD$488.2 million

TTM: trailing 12 months

Shorting Molecular Templates shares

There are currently 1.2 million Molecular Templates shares held short by investors – that's known as Molecular Templates's "short interest". This figure is 11.4% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting Molecular Templates shares can be evaluated.

Molecular Templates's "short interest ratio" (SIR)

Molecular Templates's "short interest ratio" (SIR) is the quantity of Molecular Templates shares currently shorted divided by the average quantity of Molecular Templates shares traded daily (recently around 279835.44018059). Molecular Templates's SIR currently stands at 4.43. In other words for every 100,000 Molecular Templates shares traded daily on the market, roughly 4430 shares are currently held short.

However Molecular Templates's short interest can also be evaluated against the total number of Molecular Templates shares, or, against the total number of tradable Molecular Templates shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Molecular Templates's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Molecular Templates shares in existence, roughly 20 shares are currently held short) or 0.0448% of the tradable shares (for every 100,000 tradable Molecular Templates shares, roughly 45 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Molecular Templates.

Find out more about how you can short Molecular Templates stock.

Molecular Templates share dividends

We're not expecting Molecular Templates to pay a dividend over the next 12 months.

Have Molecular Templates's shares ever split?

Molecular Templates's shares were split on a 1:11 basis on 1 August 2017. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Molecular Templates shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Molecular Templates shares which in turn could have impacted Molecular Templates's share price.

Molecular Templates share price volatility

Over the last 12 months, Molecular Templates's shares have ranged in value from as little as $7.51 up to $18.44. A popular way to gauge a stock's volatility is its "beta".

MTEM.US volatility(beta: 1.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Templates's is 1.3605. This would suggest that Molecular Templates's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Molecular Templates overview

Molecular Templates, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site